Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 […]
Published program data shows Dyne’s FORCE™ platform achieves enhanced exon skipping and prolonged dystrophin restoration in Duchenne in vivo mdx mouse model CureDuchenne provided funding to Dyne Therapeutics and we […]
Accessible gaming for people with Duchenne Individuals with Duchenne are living at a time when technology is helping to make the digital world more accessible and the real world more […]
Annual Austin Event Raises Funds to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 21, 2022) – CureDuchenne, a leading global nonprofit focused on funding and finding […]
Event Has Raised More Than $4.6 Million over the Last Decade to Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (July 19, 2022) – CureDuchenne, a leading global […]
Kevin Flanigan, MD is a leading expert in the development of gene therapies for Duchenne, and the director of the Center for Gene Therapy in the Abigail Wexner Research Institute […]
Sarepta Therapeutics Shares Clinical Data and Integrated Analysis.
Significant decreases in key biomarkers of muscle damage.
Sarepta Therapeutics is currently running multiple clinical trials in a few different countries. They are at various stages and for a range of ages. Sarepta issued an update for the […]
